CA Patent

CA3218585A1 — Composition for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions, and uses thereof

Assigned to Individual · Expires 2022-11-24 · 3y expired

What this patent protects

Provided herein are compositions and methods for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions. Specifically, the disclosure provides a method of treating an alloimmune, autoimmune, inflammatory, or mitochondrial condition in a subject, the method co…

USPTO Abstract

Provided herein are compositions and methods for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions. Specifically, the disclosure provides a method of treating an alloimmune, autoimmune, inflammatory, or mitochondrial condition in a subject, the method comprising: administering a calcineurin inhibitor and a cytochrome p450 inhibitor, wherein calcineurin inhibitor comprising cyclosporine, tacrolimus, pimecrolimus, or analogs or derivatives thereof. Further disclosed are cytochrome p450 inhibitors that can be used for the method.

Drugs covered by this patent

Patent Metadata

Patent number
CA3218585A1
Jurisdiction
CA
Classification
Expires
2022-11-24
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.